Abstract: A method of treating a mammal comprises administering to a mammal an effective amount to provide a reduction inflammation in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8- positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 independently are hydrogen, lower alkyl of 1 to 6 carbons, halogen or lower alkoxy of 1 to 6 carbons; R.sub.5 and R.sub.5 ' independently are hydrogen or lower alkyl of 1 to 6 carbons; Y is oxygen or sulfur; Z is n-alkyl having 2 to 10 carbons, cyclo or branch-chained alkyl of 3 to 10 carbons, and straight chain alkenyl having 2 to 10 carbons, or cyclo or branched chained alkenyl of 3 to 10 carbons, and the Z-Y substituent is in a 1,2 (ortho) or 1,3 (meta) position on the phenyl ring relative to the ethene moiety; A is (CH.sub.2).sub.n where n is 0-5, lower branched chain alkyl having 3 to 6 carbons, cycloalkyl having 3 to 6 carbons, alkenyl having 2 to 6 carbons and 1 or 2 double bonds, alkynyl having 2 to 6 carbons and 1 or 2 triple bonds; B is COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, CONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.11, CH.sub.2 OCOR.sub.11, CHO, CH(OR.sub.12).sub.2, CHOR.sub.

Abstract: Compounds that provide non-teratogenic effects and lack irritation to the skin are shown in the formula below where the partially drawn ring signifies an aromatic ring which may be carbocyclic or heteroaromatic, 6-membered or 5-membered, and may be condensed with another ring. R.sub.1 is lower alkyl, Cl, Br, or I, R.sub.2 is H, lower alkyl, Cl, Br, or I, and R.sub.3 is lower alkyl, Cl, Br, I, or is an ether, thioether, ester, thioester, amine or substituted amine group.

Abstract: A drawer loading cassette system for a surgical instrument includes a control cabinet and an assembly head disposed therein which includes a plurality of rollers mounted in circular pattern with each roller having a rotation axis generally parallel to an assembly heads central axis. The assembly head is mounted in the cabinet for rotation about the assembly head central axis and a drawer, configured for engagement with a tubing management cassette, is movably attached to the cabinet in order to provide an open position for loading the the cassette and a closed position for engaging a section of tubing supported by the cassette with the rollers.

Abstract: Methods for disinfecting a lens is disclosed. The methods comprise contacting a lens to be disinfected in a liquid medium with at least one chlorine dioxide precursor in the presence of at least one activator component selected from organic acid anhydrides, oxygen-releasing components and mixtures thereof to effect formation of chlorine dioxide from the chlorine dioxide precursor, thereby disinfecting the lens. Compositions useful in the above-noted methods are also disclosed.

Abstract: Apparatus and method for measuring ophthalmic formulation retention on the surface of an eye include dissolving a fluorescent macromolecule in an ophthalmic formulation to form a fluorescently labelled formulation; topically administering the fluorescently labelled formulation to an eye, said fluorescently labelled formulation forming a thin film on the eye surface. Apparatus is provided for illuminating the eye to cause fluorescence of the fluorescently labelled formulation as the fluorescently labelled formulation thin film is eliminated from the eye by normal blinking and lacrimation; and for measuring fluorescence from the thin film as a function of time.

Abstract: Retinoid like activity is exhibited by compounds of the formula ##STR1## wherein the R.sub.1 -R.sub.6 groups are independently H or straight chain or branched chain lower alkyl or cycloalkyl of 1 to 6 carbons; X symbolizes an ester or thioester linkage, Y is lower branched chain alkyl having 2 to 6 carbons, cycloalkyl having 3 to 6 carbons or is (CH.sub.2).sub.n where n is an integer between 0 to 6 or an alkenyl group of 2 to 6 carbons, and having 1 or 2 double bonds, or an alkynyl group of 2 to 6 carbons; and Z is H, OH, OR', OCOR', --COOH or a pharmaceutically acceptable salt, COOR.sub.8, COONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.11, CH.sub.2 OCOR.sub.11, CHO, CH(OR.sub.12), CHOR.sub.13 O, --COR', CR'(OR.sub.12).sub.2, or CR'OR.sub.13 O; where R' is an alkyl, cycloalkyl or alkenyl group containing 1-5 carbons, R.sub.8 is an alkyl group of 1-10 carbons, or a cycloalkyl group of 5-10 carbons, or R.sub.8 is phenyl or lower alkylphenyl, R.sub.9 and R.sub.

Abstract: Anti-inflammatory 4-substituted 2-furanones are made from intermediates having the formula ##STR1## where R.sub.1, R.sub.2 and R.sub.3 independently are n-or branched chain alkyl of 1 to 6 carbons. These compounds can be used as intermediates to produce 4-substituted 2-furanones which are anti-inflammatory agents.

Abstract: A product delivery system for delivering sterile liquid product having a positive shut-off valve to prevent back flow of liquid and air into the system. The product delivery system comprises a compressible reservoir, a flexible delivery element extending from the reservoir, and a shut-off valve movable from a closed position to an opened position, the hollow interior of the delivery element being closed when the shut-off valve is in its closed position and open when the shut-off valve is in its open position to prevent the back flow of the delivered liquid product and air into the delivery element and reservoir to thereby maintain the sterility of the liquid product contained within the reservoir and the delivery element.

Abstract: The present invention relates to 2-decarboxyl-2-acylthioalkyl prostaglandins that are potent ocular hypotentives, and are particularly suitable for the management of glaucoma.

Abstract: The present invention relates to cyclopentane heptenylsulfinylalkyl and heptanylsulfinylalkyl-2-aliphatic or arylaliphatic derivatives. In particular, heptenylsulfinylmethyl and heptanylsulfinylmethyl 2-aliphatic or arylaliphatic derivatives, substituted at the 3 and/or 5 position of the cyclopentane ring with radicals selected from the group consisting of hydroxy, alkylcarboxy and mixtures thereof, are disclosed. These compounds are useful as ocular hypotensives.

Abstract: A composition and methods useful for making such compositions and for using such compositions to destroy hydrogen peroxide in a liquid aqueous medium, such as that used to disinfect contact lenses, are disclosed. The composition comprises a coated core containing at least one hydrogen peroxide destroying component effective when released into a liquid aqueous medium to destroy or cause the destruction of hydrogen peroxide present in the liquid aqueous medium, and a barrier coating acting to substantially prevent the release of the hydrogen peroxide destroying component for a period of time after the composition is initially contacted with a hydrogen peroxide-containing liquid aqueous medium. The barrier coating is substantially water soluble, preferably includes polyvinylpyrrolidone and is applied as a substantially dry, solid material.

Abstract: A method for treating hydrophilic and rigid gas permeable contact lenses, as well as the manufacture of protein adhesion resistant and gas permeable enhanced lenses, is obtained through purging the hydrated contact lens, formed from polymer comprising hydrogen atoms, substantially all water and oxygen, and thereafter exposing the purged contact lens to a fluorine-containing gas in non-plasma conditions for a period of time and at a temperature sufficient to replace hydrogen atoms in the polymer in order to inhibit protein deposits on the contact lens. The conditions of fluorine exposure can be controlled in order to provide a gas permeable enhanced contact lens.

Abstract: A method for generating chlorine dioxide which involves contacting a stable precursor with a transition metal in a buffered aqueous medium.

Abstract: An apparatus for inspecting a test lens, such as an intraocular lens, comprising a light source and collimating lens positioned to receive light from the light source and direct collimated light to the test lens. A plurality of targets are positionable at the object focal plane of the collimating lens so that there is an image of the target at the image focal space of the test lens. The image of the target has generally radially extending and alternating first and second sectors with each of the first sectors being relatively light and each of the second sectors being relatively dark. Modulation transfer function is determined by determining the image contrast along a combination of selected ring-shaped regions of the image.

Abstract: A system for providing controlled release of an active agent in an eye includes a device with a shape thereof for enabling placement of the device under a conjunctiva of an eye and additionally preventing migration of the device in the eye after placement of the device under the conjunctiva. The device may be formed of a material permeable to the passage of an agent disposed in said device. In addition, a tracer may be incorporated in the device to enable visual indication of the amount of active agent in said device when said device is disposed under the conjunctiva. To selectively treat specific areas of the eye, an impermeable layer may be provided for preventing diffusion of the active agent from a selected area of the device.

Abstract: A compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals containing 1 to 4 carbon atoms, R.sub.2 and R.sub.3 are independently selected from the group consisting of H, OXO, and alkyl radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as alteration in the rate of fluid transport in the gastrointestinal tract, reduction in intraocular pressure, and increase in renal fluid flow.

Abstract: The process of reproducibly making a wholly spuncasted, non-truncated, ballasted soft contact lens containing a compound anterior surface. The process comprises spincasting a polymer-forming, lens forming monomeric mixture in a cavity mold having a surface that is offset to allow for generation of a prismatic ballast, a compound curvature and a central axis that is symmetrical to the peripheral edge of the lens being formed. This is done by rotating the monomer mixture in the mold whereby the mixture replicates the mold's surface while at the same time undergoes polymerization and forms a prismatic lens with the central axis of its posterior surface symmetrical to its peripheral edge, a corneal bowl free of the compound curvature and possessing a thickness profile that is asymmetrical with respect to its geometric center.

Abstract: The present invention provides novel carbonic anhyrase inhibitors represented by the structural formula: ##STR1## wherein R.sub.1 and R.sub.2 are, for example, independently (a) hydrogen; or(b) OR.sub.4, wherein R.sub.4 is hydrogen or C.sub.1-7 alkyl; or(c) NR.sub.5 R.sub.6, wherein R.sub.5 and R.sub.6 are independently hydrogen, or C.sub.1-7 alkyl, or C.sub.1-7 alkyl substituted with one or more halogen or OR.sub.4 ; or(d) --COR.sub.7, wherein R.sub.7 is hydrogen, C.sub.1-7 alkyl, or NR.sub.5 R.sub.6 ; or(e) --SR.sub.8, wherein R.sub.8 is hydrogen or C.sub.1-7 alkyl, or C.sub.1-7 alkyl substituted with one or more halogen, or OR.sub.4 ; or(f) C.sub.1-7 alkyl, or C.sub.1-7 alkyl substituted with one or more halogen, or OR.sub.4 or NR.sub.5 R.sub.6 ; or(g) R.sub.1 and R.sub.2 are together(i) .dbd.O, or(ii) .dbd.NOR.sub.8 or(iii) .dbd.S;and R.sub.3 is(h) C.sub.1-7 alkyl or C.sub.1-7 substituted with one or more halogen, OR.sub.4 or NR.sub.5 R.sub.6.

Abstract: Anti-inflammatory 4-substituted 2-furanones are made from intermediates having the formulas: ##STR1##